Abstract：
UNASSIGNED: Polycystic ovary syndrome (PCOS) is an endocrine gynaecological disorder that affects many women of childbearing age.
UNASSIGNED: To evaluate the efficacy and safety of glucose-like peptide-1 receptor agonists for obese women with PCOS.
UNASSIGNED: We searched the PubMed, Embase, WOS, and Cochrane Libarary databases up to June 2023. Studies were eligible if they were randomised controlled trials (RCTs) comparing GLP-1RAs against any other treatments for patients with PCOS.
UNASSIGNED: Overall, a total of 8 RCTs were included in this review, 7 of the RCTs compared GLP-1RAs with metformin, and 1 RCT compared GLP-1Ras with dapagliflozin. Compared with control group, GLP-1RAs were more effective at improving insulin sensitivity, reducing BMI, and resulting in a smaller waist circumference.
UNASSIGNED: GLP-1RAs may be a good option for obese women with PCOS, especially those with insulin resistance. However, high-quality studies are also needed in the future to assess the efficacy of GLP-1RAs in women with PCOS.
UNASSIGNED: To evaluate the efficacy and safety of glucose-like peptide-1 receptor agonists for obese women with PCOS.
UNASSIGNED: We searched the PubMed, Embase, WOS, and Cochrane Libarary databases up to June 2023. Studies were eligible if they were randomised controlled trials (RCTs) comparing GLP-1RAs against any other treatments for patients with PCOS.
UNASSIGNED: Overall, a total of 8 RCTs were included in this review, 7 of the RCTs compared GLP-1RAs with metformin, and 1 RCT compared GLP-1Ras with dapagliflozin. Compared with control group, GLP-1RAs were more effective at improving insulin sensitivity, reducing BMI, and resulting in a smaller waist circumference.
UNASSIGNED: GLP-1RAs may be a good option for obese women with PCOS, especially those with insulin resistance. However, high-quality studies are also needed in the future to assess the efficacy of GLP-1RAs in women with PCOS.
摘要：
■多囊卵巢综合征（PCOS）是一种影响许多育龄妇女的内分泌妇科疾病。
■评估葡萄糖样肽-1受体激动剂对PCOS肥胖女性的疗效和安全性。
■我们搜索了PubMed，Embase,WOS,和截至2023年6月的CochraneLibarary数据库。如果是将GLP-1RA与PCOS患者的任何其他治疗方法进行比较的随机对照试验（RCT），则这些研究符合资格。
■总的来说，本综述共纳入8项RCT,7项RCT比较了GLP-1RA与二甲双胍，1个RCT比较了GLP-1Ras与达格列净。与对照组相比,GLP-1RA在改善胰岛素敏感性方面更有效，降低BMI,并导致较小的腰围。
■GLP-1RA对于患有PCOS的肥胖女性可能是一个不错的选择，尤其是那些有胰岛素抵抗的人。然而,未来还需要高质量的研究来评估GLP-1RAs在PCOS女性患者中的疗效.
■评估葡萄糖样肽-1受体激动剂对PCOS肥胖女性的疗效和安全性。
■我们搜索了PubMed，Embase,WOS,和截至2023年6月的CochraneLibarary数据库。如果是将GLP-1RA与PCOS患者的任何其他治疗方法进行比较的随机对照试验（RCT），则这些研究符合资格。
■总的来说，本综述共纳入8项RCT,7项RCT比较了GLP-1RA与二甲双胍，1个RCT比较了GLP-1Ras与达格列净。与对照组相比,GLP-1RA在改善胰岛素敏感性方面更有效，降低BMI,并导致较小的腰围。
■GLP-1RA对于患有PCOS的肥胖女性可能是一个不错的选择，尤其是那些有胰岛素抵抗的人。然而,未来还需要高质量的研究来评估GLP-1RAs在PCOS女性患者中的疗效.
